ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections

被引：7

作者：

Burgos, Rodrigo M. ^{[1
]}

Rodvold, Keith A. ^{[1
,2
]}

机构：

[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA

[2] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA

来源：

FUTURE MICROBIOLOGY | 2019年 / 14卷 / 06期

关键词：

acute pyelonephritis; antibiotics; antimicrobial agents; complicated urinary tract infection; efficacy; fosfomycin; pharmacodynamics; pharmacokinetics; safety; tolerability; ZTI-01; ESCHERICHIA-COLI; INTRAVENOUS FOSFOMYCIN; RESISTANCE; PYELONEPHRITIS; PHOSPHONOMYCIN; TAZOBACTAM;

D O I：

10.2217/fmb-2018-0303

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Fosfomycin is a bactericidal antibiotic available since the 1970s whose intravenous formulation has been available in many countries outside the USA. Given the rise in drug-resistant bacteria, its introduction into the US market has become a necessity for addressing these organisms. This review provides an overview of the microbiology, clinical pharmacology and initial clinical experiences of the intravenous fosfomycin product (ZTI-01) that is undergoing clinical development in the USA for the treatment of complicated urinary tract infections and acute pyelonephritis.

引用

页码：461 / 475

页数：15

共 49 条

[1]

Achaogen Inc, 2018, HIGHL PRESCR INF ZEN

[2]

Allergan USA Inc, 2018, HIGHL PRESCR INF MON

[3] Management of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance [J].

Bader, Mazen S. ;

Hawboldt, John ;

Brooks, Annie .

POSTGRADUATE MEDICINE, 2010, 122 (06) :7-15

[4] Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3-or OXA-48-producing Escherichia coli [J].

Berleur, M. ;

Guerin, F. ;

Massias, L. ;

Chau, F. ;

Poujade, J. ;

Cattoir, V. ;

Fantin, B. ;

de lastours, V. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (11) :3074-3080

[5]

Bhavnani SM, 2017, AM SOC MICR MICR 201

[6] PHOSPHONOMYCIN - STRUCTURE AND SYNTHESIS [J].

CHRISTENSEN, BG ;

LEANZA, WJ ;

BEATTIE, TR ;

PATCHETT, AA ;

ARISON, BH ;

ORMOND, RE ;

KUEHL, FA ;

ALBERSSC.G ;

JARDETZKY, O .

SCIENCE, 1969, 166 (3901) :123-+

[7]

Clancy CJ, 2017, ASM MICR 2017 NEW OR

[8] Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae [J].

Diep, John K. ;

Sharma, Rajnikant ;

Ellis-Grosse, Evelyn J. ;

Abboud, Cely S. ;

Rao, Gauri G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)

[9] Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance [J].

Docobo-Perez, F. ;

Drusano, G. L. ;

Johnson, A. ;

Goodwin, J. ;

Whalley, S. ;

Ramos-Martin, V. ;

Ballestero-Tellez, M. ;

Rodriguez-Martinez, J. M. ;

Conejo, M. C. ;

van Guilder, M. ;

Rodriguez-Bano, J. ;

Pascual, A. ;

Hope, W. W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) :5602-5610

[10]

Drusano GL, 2018, ANTIMICROB AGENTS CH

← 1 2 3 4 5 →